Engel Law PLLC is investigating whether fair value to Magenta shareholders will result from the proposed merger between Magenta Therapeutics, Inc. (NASDAQ: MGTA) and Dianthus Therapeutics, Inc., pursuant to which pre-mergerDianthus stockholders are expected to own approximately 78.7% of the combined company and pre-merger Magenta stockholders are expected to own approximately 21.3% of the combined company.
The Firm’s investigation concerns:
(i) whether the Company’s board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction;
(ii) whether the merger consideration adequately compensates the Company’s shareholders; and
(iii) whether all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.